Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03446976 · ClinicalTrials.gov registry record · Phase 1
CT-P13 (Infliximab) Subcutaneous Administration by Pre-filled Syringe and Auto-injector in Healthy Subjects
A Phase 1 study, sponsored by Celltrion.
- Completed
- Registry status
- Phase 1
- Development phase
- 218
- Enrollment target
NCT03446976 is a Phase 1 study that has completed, run by Celltrion. The registered enrollment target is 218 participants.
The verdict
NCT03446976, a Phase 1 study, has completed, sponsored by Celltrion.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 218 participants
- Enrollment target
Study Summary
This study compares two administration methods of CT-P13. Half of participants will receive CT-P13 by pre-filled syringe while the other half will receive CT-P13 by auto-injector.
Interventions
- BIOLOGICAL CT-P13 SC Auto-injector
- BIOLOGICAL CT-P13 SC Pre-filled Syringe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 218 participants |
| Start Date | 2018-02-21 |
| Est. Completion | 2018-07-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03446976
The ClinicalTrials.gov registry entry for NCT03446976 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 218 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celltrion, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CT-P13 SC Auto-injector is the first listed.
NCT03446976 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03446976 about?
NCT03446976 is a clinical study titled "CT-P13 (Infliximab) Subcutaneous Administration by Pre-filled Syringe and Auto-injector in Healthy Subjects". This study compares two administration methods of CT-P13. Half of participants will receive CT-P13 by pre-filled syringe while the other half will receive CT-P13 by auto-injector.
What is the current status of trial NCT03446976?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 218 participants. The study started on 2018-02-21. Estimated completion is 2018-07-26.
What interventions are being tested in trial NCT03446976?
The interventions under investigation include: CT-P13 SC Auto-injector (BIOLOGICAL), CT-P13 SC Pre-filled Syringe (BIOLOGICAL).
Who is sponsoring clinical trial NCT03446976?
This trial is sponsored by Celltrion, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.